Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulse rhythm01:30

Pulse rhythm

1.7K
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
1.7K
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

1.7K
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
1.7K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

798
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
798
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

810
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
810
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

761
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
761
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

461
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
461

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peak QRS/T ratio and the spatial ventricular gradient differentiate acute vs chronic left bundle branch block after transcatheter aortic valve replacement.

Heart rhythm O2·2026
Same author

Electrophysiological observations during and after transcatheter aortic valve replacement.

Heart rhythm·2026
Same author

HRS position statement: Changing the tide in CPR and AED education for students in the United States.

Heart rhythm·2026
Same author

Establishing a national cardiopulmonary resuscitation program in Indian high schools and colleges: An expert collaborative call to action and implementation model.

Heart rhythm·2026
Same author

Mechanisms Underlying Alterations in Cardiac Conduction After Transcatheter Aortic Valve Replacement.

JAMA cardiology·2025
Same author

Larger spatial ventricular gradient magnitude is associated with higher rates of response to cardiac resynchronization therapy.

Heart rhythm O2·2025
Same journal

Sparganosis.

The New England journal of medicine·2026
Same journal

Caring for an Aging America - The Looming Crisis of the Long-Term-Care Workforce.

The New England journal of medicine·2026
Same journal

For Those Left Behind.

The New England journal of medicine·2026
Same journal

Colliding Forces - The Aging of the Baby Boom Generation and Contracting Nursing-Home Supply.

The New England journal of medicine·2026
Same journal

Mandated State-Level Surveillance of Assisted Reproductive Technology - An Emerging Threat in the United States.

The New England journal of medicine·2026
Same journal

Ebola at 50 - Lessons for Outbreak Response and Preparedness.

The New England journal of medicine·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Acute Myocardial Infarction in Rats
07:45

Acute Myocardial Infarction in Rats

Published on: February 16, 2011

54.6K

Wearable Cardioverter-Defibrillator after Myocardial Infarction.

Jeffrey E Olgin1, Mark J Pletcher1, Eric Vittinghoff1

  • 1From the Division of Cardiology, Department of Medicine, the UCSF Center for the Prevention of Sudden Death (J.E.O., C.M., B.K.L.) and the Department of Epidemiology and Biostatistics (M.J.P., E.V., T.F.H., F.L., J.A.S., S.H.), University of California, San Francisco, San Francisco; the Department of Electrocardiology, Medical University of Lodz, Lodz, Poland (J.W.); McLeod Regional Medical Center, Florence, SC (R.M.); Ochsner Medical Center and Ochsner Clinical School, University of Queensland School of Medicine, New Orleans (D.P.M.); Hartford Healthcare Heart and Vascular Institute and University of Connecticut School of Medicine, Hartford (S.Z.); Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (A.E.B.); Gill Heart Institute, University of Kentucky, and Veterans Affairs Medical Center, Lexington (C.S.E.); the Department of Internal Medicine, University of Michigan, Michigan Medicine, Ann Arbor (E.H.C.); Stony Brook Medicine, Stony Brook, NY (E.R.); and First Department of Medicine-Cardiology, University Medical Center Mannheim, Mannheim, and DZHK (German Center for Cardiovascular Research), Heidelberg - both in Germany (M.B.).

The New England Journal of Medicine
|October 4, 2018
PubMed
Summary
This summary is machine-generated.

A wearable cardioverter-defibrillator did not significantly reduce arrhythmic death in patients with low ejection fraction after myocardial infarction. This wearable device did not prove effective in preventing sudden cardiac death during the high-risk post-MI period.

More Related Videos

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.7K
Histological Quantification of Chronic Myocardial Infarct in Rats
09:45

Histological Quantification of Chronic Myocardial Infarct in Rats

Published on: December 11, 2016

15.4K

Related Experiment Videos

Last Updated: May 5, 2026

Acute Myocardial Infarction in Rats
07:45

Acute Myocardial Infarction in Rats

Published on: February 16, 2011

54.6K
Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.7K
Histological Quantification of Chronic Myocardial Infarct in Rats
09:45

Histological Quantification of Chronic Myocardial Infarct in Rats

Published on: December 11, 2016

15.4K

Area of Science:

  • Cardiology
  • Medical Devices
  • Clinical Trials

Background:

  • Patients with low ejection fraction after myocardial infarction face a high risk of sudden death.
  • Implantable cardioverter-defibrillators are typically contraindicated in the early post-myocardial infarction period.
  • The efficacy of wearable cardioverter-defibrillators in this high-risk window was previously unclear.

Purpose of the Study:

  • To evaluate the effectiveness of a wearable cardioverter-defibrillator in reducing sudden death and arrhythmic death in patients with acute myocardial infarction and low ejection fraction.
  • To compare the incidence of arrhythmic death and all-cause mortality between patients using a wearable cardioverter-defibrillator and those receiving guideline-directed therapy alone.

Main Methods:

  • A randomized controlled trial was conducted with 2302 participants.
  • Patients with acute myocardial infarction and ejection fraction ≤35% were assigned 2:1 to receive a wearable cardioverter-defibrillator plus guideline-directed therapy or guideline-directed therapy alone.
  • The primary outcome was a composite of sudden death or death from ventricular tachyarrhythmia at 90 days (arrhythmic death).

Main Results:

  • Arrhythmic death occurred in 1.6% of the device group versus 2.4% of the control group (relative risk, 0.67; P=0.18).
  • All-cause mortality was lower in the device group (3.1%) compared to the control group (4.9%; relative risk, 0.64; P=0.04).
  • The wearable cardioverter-defibrillator delivered appropriate shocks to 1.3% of recipients and inappropriate shocks to 0.6%.

Conclusions:

  • The wearable cardioverter-defibrillator did not significantly reduce the primary outcome of arrhythmic death at 90 days in patients with recent myocardial infarction and low ejection fraction.
  • While all-cause mortality showed a trend towards reduction with the device, the primary endpoint was not met.
  • Further research may be needed to define the role of wearable cardioverter-defibrillators in specific patient populations or timeframes.